Chief Scientific Officer Yoshitsugu Shitaka, Ph.D., won’t be so lucky. Astellas intends to create the new role of chief ...

Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that the following changes to its management structure effective April 1, 2025.

Navigating regulatory hurdles in the U.S. and Europe, plus fierce competition from rival Apellis, Astellas’ geographic ...

Astellas has changed its management structure, establishing new top management positions and making personnel changes. The goal of the change is to promote drug discovery activities swiftly and ...

Not satisfied with simply changing personnel, Japanese drugmaker Astellas has announced a new management structure, effective ...

Minds + Assembly, a 2024 MM+M Agency 100 honoree, added Chuck Hemann as chief integration officer and Jonathan Woodring as ...

Japanese drugmaker Astellas Pharma says it has submitted a New Drug Application (NDA) to Japan’s Ministry of Health, Labor ...

Pfizer terminated partnership with Sangamo on hemophilia A gene therapy despite positive Phase 3 data. Find out why SGMO ...

Funding for the acquisition will come from a combination of cash, loans and a commercial paper instrument, according to Astellas, which estimates that the deal will help it meet financial targets ...

Astellas is ready to launch its first digital ... The companies are now hoping to sell the platform to commercial health programmes in the US. The patient monitoring platform puts heart failure ...